EP3240535A4 - Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite - Google Patents

Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite Download PDF

Info

Publication number
EP3240535A4
EP3240535A4 EP15876164.3A EP15876164A EP3240535A4 EP 3240535 A4 EP3240535 A4 EP 3240535A4 EP 15876164 A EP15876164 A EP 15876164A EP 3240535 A4 EP3240535 A4 EP 3240535A4
Authority
EP
European Patent Office
Prior art keywords
glaucoma
ophthalmic solutions
conjunctivitis treatment
conjunctivitis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15876164.3A
Other languages
German (de)
English (en)
Other versions
EP3240535A1 (fr
Inventor
George ANASTASSOV
Lekhram CHANGOER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axim Biotechnologies Inc
Original Assignee
Axim Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axim Biotechnologies Inc filed Critical Axim Biotechnologies Inc
Publication of EP3240535A1 publication Critical patent/EP3240535A1/fr
Publication of EP3240535A4 publication Critical patent/EP3240535A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15876164.3A 2014-12-30 2015-12-29 Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite Withdrawn EP3240535A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098007P 2014-12-30 2014-12-30
PCT/US2015/067855 WO2016109531A1 (fr) 2014-12-30 2015-12-29 Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Publications (2)

Publication Number Publication Date
EP3240535A1 EP3240535A1 (fr) 2017-11-08
EP3240535A4 true EP3240535A4 (fr) 2018-08-08

Family

ID=56162983

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15876164.3A Withdrawn EP3240535A4 (fr) 2014-12-30 2015-12-29 Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite

Country Status (4)

Country Link
US (2) US9814695B2 (fr)
EP (1) EP3240535A4 (fr)
MA (1) MA41299A (fr)
WO (1) WO2016109531A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2547323T3 (pl) 2010-03-17 2016-07-29 Novaliq Gmbh Kompozycja farmaceutyczna do leczenia podwyższonego ciśnienia wewnątrzgałkowego
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
CN113679699B (zh) 2012-09-12 2022-10-28 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
CN110403923B (zh) 2015-09-30 2021-09-21 诺瓦利克有限责任公司 半氟化化合物和其组合物
WO2018055101A1 (fr) 2016-09-23 2018-03-29 Novaliq Gmbh Compositions ophtalmiques contenant de la cyclosporine
AU2017333420A1 (en) 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
CA3058097C (fr) 2017-04-21 2024-01-02 Novaliq Gmbh Compositions d'iode
WO2018205022A1 (fr) * 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Formulation pour l'administration d'un médicament pour les yeux
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es) 2017-09-27 2020-07-29 Novaliq Gmbh Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
WO2019068763A1 (fr) 2017-10-04 2019-04-11 Novaliq Gmbh Compositions ophtalmiques comprenant du f6h8
AU2019248216A1 (en) * 2018-04-04 2020-11-12 Eye Co Pty Ltd Low THC hemp extract and method of treatment or prevention of an eye disease
CN112153970A (zh) 2018-04-27 2020-12-29 诺瓦利克有限责任公司 用于治疗青光眼的包含他氟前列素的眼用组合物
US11077150B2 (en) * 2018-10-09 2021-08-03 Massoumeh Kharazmi Methods and compositions for treatment of eye conditions
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3923907B1 (fr) 2019-02-13 2024-09-25 Novaliq GmbH Compositions et procédés pour le traitement de la néovascularisation oculaire
KR20220080045A (ko) * 2019-04-24 2022-06-14 인메드 파마슈티컬스 인코포레이티드 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법
KR20220058577A (ko) 2019-09-06 2022-05-09 노바리크 게엠베하 포도막염 치료를 위한 안과용 조성물
CN119384280A (zh) * 2022-06-16 2025-01-28 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
WO2026047389A1 (fr) * 2024-08-30 2026-03-05 Vicadia Lda Administration topique de formulations à base de cannabinoïdes pour allergie oculaire et inflammation dans des maladies ophtalmiques
WO2026062414A1 (fr) * 2024-09-19 2026-03-26 Vicadia Lda Administration iontophorétique intraoculaire d'une formulation à base de cannabinoïdes, associée à d'autres agents pour la neuroprotection dans des conditions ophtalmiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138707A1 (fr) * 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Compositions lkktet et/ou lkktnt et procédés de traitement ou de prévention de la détérioration, de la lésion ou de l'altération des tissus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US7612101B2 (en) * 2006-04-24 2009-11-03 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007046086A1 (de) 2007-09-26 2009-04-09 Heinz Prof. Dr. Letzel Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen
CA2760460C (fr) 2009-04-28 2019-04-02 Alltranz Inc. Formulations transdermiques de cannabidiol renfermant un agent d'amelioration de la penetration et methodes d'utilisation desdites formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138707A1 (fr) * 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Compositions lkktet et/ou lkktnt et procédés de traitement ou de prévention de la détérioration, de la lésion ou de l'altération des tissus

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GREEN K ET AL: "Cannabinoid penetration and chronic effects in the eye", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, vol. 24, no. 2, 1 February 1977 (1977-02-01), pages 197 - 205, XP022970848, ISSN: 0014-4835, [retrieved on 19770201], DOI: 10.1016/0014-4835(77)90260-3 *
GREEN K ET AL: "Ocular penetration of topical [Delta]9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site", CURRENT EYE RESEARCH, INFORMA HEALTHCARE USA, US, vol. 21, no. 1, 1 January 2000 (2000-01-01), pages 566 - 570, XP009506367, ISSN: 0271-3683, [retrieved on 20000702], DOI: 10.1076/0271-3683(200007)2111-ZFT566 *
GROTENHERMEN F: "Cannabinoids for therapeutic use: Designing systems to increase efficacy and reliability", AMERICAN JOURNAL OF DRUG DELI, ADIS INTERNATIONAL, AUCKLAND ; YARDLEY, PA, USA, vol. 2, no. 4, 1 January 2004 (2004-01-01), pages 229 - 240, XP008134461, ISSN: 1175-9038, DOI: 10.2165/00137696-200402040-00003 *
KEARSE E C ET AL: "Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of [Delta]9-tetrahydrocannabinol", vol. 20, no. 6, 1 January 2000 (2000-01-01), pages 496 - 501, XP009506437, ISSN: 0271-3683, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/abs/10.1076/0271-3683%28200006%292061-YFT496> [retrieved on 20090702], DOI: 10.1076/0271-3683(200006)20:6;1-Y;FT496 *
KETAN HIPPALGAONKAR ET AL: "Enhanced Solubility, Stability, and Transcorneal Permeability of Delta-8-Tetrahydrocannabinol in the Presence of Cyclodextrins", AAPS PHARMSCITECH, SPRINGER NEW YORK LLC, US, vol. 12, no. 2, 3 June 2011 (2011-06-03), pages 723 - 731, XP019925535, ISSN: 1530-9932, DOI: 10.1208/S12249-011-9639-5 *
See also references of WO2016109531A1 *

Also Published As

Publication number Publication date
US9814695B2 (en) 2017-11-14
MA41299A (fr) 2017-11-07
US9844530B1 (en) 2017-12-19
US20160184259A1 (en) 2016-06-30
EP3240535A1 (fr) 2017-11-08
WO2016109531A1 (fr) 2016-07-07

Similar Documents

Publication Publication Date Title
EP3240535A4 (fr) Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
IL265497B (en) Methods for treating eye diseases
EP3240510A4 (fr) Dispositifs et procédés de traitement du glaucome
EP3210526A4 (fr) Appareil ophtalmique
EP3157463A4 (fr) Procédés et dispositifs de traitement de troubles oculaires postérieurs
EP3096617A4 (fr) Compositions et méthodes de traitement de maladies oculaires
EP3177732A4 (fr) Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
EP3160471A4 (fr) Composition ophtalmique
EP3218850A4 (fr) Procédés et appareil pour l&#39;amélioration de la vision
EP3160405A4 (fr) Traitement de l&#39;oreille
EP3212137A4 (fr) Systèmes et procédés pour le traitement d&#39;affections oculaires
EP3019243A4 (fr) Procédés pour traiter ou prévenir des états ophtalmologiques
EP3192478A4 (fr) Dispositif de traitement ophtalmique et procédé d&#39;entrainement associé
EP3240612A4 (fr) Procédés de traitement de maladies rétiniennes
EP3108838A4 (fr) Dispositif de traitement de maintien
EP3191185A4 (fr) Dispositif de traitement ciblé de dermatoses
EP3142664A4 (fr) Compositions et méthodes pour le traitement et le diagnostic d&#39;affections oculaires
EP3213723A4 (fr) Dispositif de traitement de syndrome d&#39;oeil sec et de renforcement de la vue
EP3089748A4 (fr) Traitement de la néovascularisation oculaire
EP3117210A4 (fr) Compositions et méthodes utilisables en vue du traitement d&#39;infections et de maladies oculaires
EP3056599A4 (fr) Dispositif de traitement de vêtement
EP3216451A4 (fr) Composition ophtalmique aqueuse
EP3099304A4 (fr) Nouveaux agents thérapeutiques pour le traitement du glaucome
EP3118671A4 (fr) Lentille ophtalmique et procédé de conception de lentille ophtalmique
EP3209295A4 (fr) Méthodes de traitement de troubles oculaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170609

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20180705

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/352 20060101AFI20180629BHEP

Ipc: A61K 9/08 20060101ALI20180629BHEP

Ipc: A61K 31/05 20060101ALI20180629BHEP

Ipc: A61P 25/00 20060101ALI20180629BHEP

Ipc: A61K 9/00 20060101ALI20180629BHEP

17Q First examination report despatched

Effective date: 20190723

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200204